Oscar Health Inc (OSCR) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

GuruFocus.com11-08

Revenue: $2.4 billion, a 68% increase year over year. Medical Loss Ratio (MLR): Increased 80 basis points to 84.6%. Adjusted EBITDA: $312 million year-to-date, a $246 million increase year over year. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481414688?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/faK.SsvkoRl42SfaizSofQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7fbbb0bde04081b60bbcb9c1c78251e7","is_english":true,"pubTime":"2024-11-08 15:35","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481414688","market":"us","top_or_hot":-1,"title":"Oscar Health Inc (OSCR) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $2.4 billion, a 68% increase year over year.\nMedical Loss Ratio (MLR): Increased 80 basis points to 84.6%.\nAdjusted EBITDA: $312 million year-to-date, a $246 million increase year over year.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/oscar-health-inc-oscr-q3-073505546.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oscar Health Inc (OSCR) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOscar Health Inc (OSCR) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 15:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oscar-health-inc-oscr-q3-073505546.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $2.4 billion, a 68% increase year over year.\nMedical Loss Ratio (MLR): Increased 80 basis points to 84.6%.\nAdjusted EBITDA: $312 million year-to-date, a $246 million increase year over year.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/oscar-health-inc-oscr-q3-073505546.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OSCR","symbol_name":"Oscar Health, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/oscar-health-inc-oscr-q3-073505546.html","article_id":"2481414688","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/faK.SsvkoRl42SfaizSofQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7fbbb0bde04081b60bbcb9c1c78251e7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481414688","pubTimestamp":1731051305,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $2.4 billion, a 68% increase year over year.Medical Loss Ratio : Increased 80 basis points to 84.6%.Adjusted EBITDA: $312 million year-to-date, a $246 million increase year over year.Net Income: $179 million year-to-date, a $300 million improvement over the same period last year.Membership: Approximately 1.65 million members, a 68% increase year over year.SG&A Expense Ratio: Improved by approximately 360 basis points year over year to 19%.Cash and Investments: Approximately $3.7 billion, including $260 million at the parent company.Capital and Surplus: Approximately $1 billion, including $575 million of excess capital.2024 Revenue Guidance: Raised to a range of $9.2 billion to $9.3 billion.2024 Adjusted EBITDA Guidance: Expected towards the high end of $160 million to $210 million.GuruFocus has detected 2 Warning Sign with NET.Oscar Health Inc  reported a 68% year-over-year increase in revenue, reaching $2.4 billion for the third quarter.Oscar Health Inc  closed the first nine","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"OSCR":"Oscar Health, Inc."},"translate_title":"Oscar Health Inc(OSCR)2024年第三季度收益看涨期权亮点：强劲的收入增长和战略……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSCR":1},"content_text":"Revenue: $2.4 billion, a 68% increase year over year.\nMedical Loss Ratio (MLR): Increased 80 basis points to 84.6%.\nAdjusted EBITDA: $312 million year-to-date, a $246 million increase year over year.\nNet Income: $179 million year-to-date, a $300 million improvement over the same period last year.\nMembership: Approximately 1.65 million members, a 68% increase year over year.\nSG&A Expense Ratio: Improved by approximately 360 basis points year over year to 19%.\nCash and Investments: Approximately $3.7 billion, including $260 million at the parent company.\nCapital and Surplus: Approximately $1 billion, including $575 million of excess capital.\n2024 Revenue Guidance: Raised to a range of $9.2 billion to $9.3 billion.\n2024 Adjusted EBITDA Guidance: Expected towards the high end of $160 million to $210 million.\n\n\nWarning! GuruFocus has detected 2 Warning Sign with NET.\n\nRelease Date: November 07, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nOscar Health Inc (NYSE:OSCR) reported a 68% year-over-year increase in revenue, reaching $2.4 billion for the third quarter.\nThe company achieved a total company adjusted EBITDA of $312 million year-to-date, representing a $246 million increase year over year.\nOscar Health Inc (NYSE:OSCR) closed the first nine months of 2024 with approximately 1.65 million members, a 68% increase year over year.\nThe company is on track to achieve net income profitability this year, marking a significant milestone.\nOscar Health Inc (NYSE:OSCR) is expanding its market presence, increasing its total addressable lives to approximately 11 million, an increase of 700,000 lives year over year.\n\n Negative Points \n\nThe medical loss ratio increased by 80 basis points year over year to 84.6%, primarily driven by higher SEP membership and a late summer COVID uptick.\nSEP member additions have been higher than anticipated, creating a headwind for the medical loss ratio.\nThe company expects a medical loss ratio towards the high end of their prior range of 80.5% to 81.5%, driven by SEP membership risk adjustment dynamics.\nOscar Health Inc (NYSE:OSCR) faces competitive pricing pressures, with some market players pricing closer to flat due to minimum MLR requirements.\nThe company acknowledges that the 15% growth assumption for the ACA market next year may be at the high end of the range due to CMS's program integrity efforts.\n\n Q & A Highlights \nQ: Can you expand on your competitive positioning for 2025, especially regarding your rate increase compared to the market? A: Mark Bertolini, CEO: Our average rate increase is about 6% versus the market at 7%. We believe the market is largely rational and stable from a pricing standpoint. While some players may chase market share, we don't think that's sustainable, and we expect a stable market this year.\nQ: Can you explain the SEP pressure and why there's more pressure than expected? A: R. Blackley, CFO: We've had more SEP additions than anticipated, which increased our top-line revenue guidance. The performance of SEP members has been on track with expectations, and utilization has been slightly favorable. The story is more about having more members than expected, which is reflected in both top-line and bottom-line performance.\nQ: Regarding your long-term guidance, should we think about the 20% CAGR coming off the higher revenue base? A: R. Blackley, CFO: We are encouraged by our year-to-date performance, which sets us up well to achieve a 20% CAGR through 2027. We won't be making any updates to the long-term guidance at this time.\nQ: Can you help us understand the implied fourth-quarter MLR and why it might be flat quarter over quarter? A: R. Blackley, CFO: COVID was a third-quarter phenomenon and won't continue. SEP additions will be lower in the fourth quarter, and we have payment integrity initiatives picking up. These factors should result in flatter growth in the fourth quarter.\nQ: Has there been any change in your thinking regarding the assumption that extended subsidies will sunset? A: Mark Bertolini, CEO: We haven't made any changes to our 2025 assumptions. We believe both parties have an incentive to ensure the program continues, as pulling back subsidies could create inflationary pressures.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481414688"}